Viewing nowCombinationEsaglitlo Tablet 10/5 mg
Empagliflozin 10mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.

MFDS item code 201701586 · Approved 2017.03.31 · Insurance code 653501590
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is a combination of empagliflozin and linagliptin, used to assist in blood sugar control for patients with type 2 diabetes by supplementing dietary and exercise therapy. By taking this medication in addition to diet and exercise, patients can achieve more effective blood sugar management.
The recommended starting dose of this drug is empagliflozin 10 mg/linagliptin 5 mg once daily. If additional glycemic control is needed in patients who tolerate empagliflozin 10 mg/linagliptin 5 mg, the dose of this drug may be increased to 25/5 mg once daily. Patients switching from combination therapy with empagliflozin and linagliptin to this drug should receive their previous doses. This drug may be taken with or without food. Swallow the tablet whole. If a dose of this drug is missed, take it as soon as remembered. However, if the time for the next dose is within 12 hours, skip the missed dose and take the next dose at the usual scheduled time. Do not take a double dose on the same day. Patients with renal impairment This drug is not recommended for improving glycemic control in patients with an estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2. No dosage adjustment is necessary in patients with an estimated glomerular filtration rate of 45 ml/min/1.73m2 or higher. Patients with hepatic impairment No dosage adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this drug is not recommended in patients with severe hepatic impairment, as it has not been studied in these patients. Older adults No dosage adjustment based on age is necessary. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.
This medication consists of two active ingredients, empagliflozin and linagliptin, primarily used for the treatment of type 2 diabetes. First, this medication should not be used in certain patients. For example, individuals with an allergy to any of its components or ingredients, type 1 diabetes patients, patients with diabetic ketoacidosis, and those undergoing dialysis should not take this medication. Patients with impaired renal function or heart failure should exercise greater caution when using this medication. Renal function can affect the efficacy of this drug, so regular kidney function tests are required before and after use. Acute pancreatitis may occur, so if severe abdominal pain persists while taking this medication, it is essential to consult a physician immediately, and if pancreatitis is suspected, discontinue the medication. Additionally, there may be a rare occurrence of a skin condition known as bullous pemphigoid, which causes blisters on the skin, indicating the need to inform medical personnel promptly if any skin abnormalities arise. Taking this medication may increase the risk of urinary and genital infections, and any symptoms of infection should be treated promptly. Symptoms of hypoglycemia may arise, especially when taken with blood glucose-lowering agents such as insulin or sulfonylureas; frequent blood sugar monitoring and caution are advised. This medication may lead to fluid volume depletion, so special attention should be paid to elderly patients or those with low blood pressure to prevent dehydration. In severe dehydration cases, it may be necessary to temporarily suspend the medication. Pregnant or breastfeeding women are advised to avoid taking this medication and should consult a physician if necessary. The safety and efficacy of this medication in children under 18 years of age have not been established, and its use is not recommended. In case of overdose, treatment may include the removal of any remaining medication from the gastrointestinal tract; therefore, adhering to the prescribed dosage is crucial. Finally, this medication should be stored out of the reach of children and kept in its original container; transferring it to another container should be avoided.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is best to maintain a storage temperature between 1 to 30 degrees Celsius. This helps keep the drug effective and safe for a longer period.
A light yellow, triangular film-coated tablet with flat sides and sharp edges.
30 tablets/PTP[(10 tablets/PTP*3)], 10 tablets/PTP[(10 tablets/PTP*1)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin 10mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 25mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 25mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 10mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Dongkoo Bio Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 25mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 10mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Boryung Pharmaceutical Co., Ltd.
Empagliflozin 25mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
Empagliflozin 10mg · Linagliptin 5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.